ATRA · Atara Biotherapeutics, Inc.

Atara Biotherapeutics disclosed that on April 30, 2026, it received a notice from Nasdaq indicating non-compliance with the $50 million minimum market value for listed securities (MVLS) requirement under Listing Rule 5450(b)(2)(A). The company has a 180-day compliance period, ending October 27, 2026, to regain compliance. If the MVLS closes at $50 million or more for 10 consecutive business days, Nasdaq will provide written confirmation of compliance. The notice does not immediately affect the listing or trading of Atara's common stock, which continues on the Nasdaq Global Select Market under the symbol ATRA. The company intends to monitor its market value and may evaluate options such as transferring to The Nasdaq Capital Market. However, there is no assurance that it will regain compliance. If it fails to do so by the Compliance Date, Nasdaq will issue a delisting notice, which the company may appeal to a Hearings Panel. This event is material as it poses a risk to the continued listing of Atara's stock, potentially impacting liquidity and investor confidence.